Oculis Holding AG (NASDAQ:OCS) Sees Significant Decrease in Short Interest

Oculis Holding AG (NASDAQ:OCS) was the target of a significant drop in short interest in the month of February. As of February 28th, there was short interest totalling 25,000 shares, a drop of 14.1% from the February 13th total of 29,100 shares. Currently, 0.1% of the shares of the company are sold short. Based on an average daily volume of 71,300 shares, the short-interest ratio is currently 0.4 days.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on OCS shares. Robert W. Baird lifted their target price on Oculis from $37.00 to $41.00 and gave the stock an “outperform” rating in a research note on Thursday, March 13th. Chardan Capital reaffirmed a “buy” rating and set a $28.00 target price on shares of Oculis in a report on Thursday, March 13th. Finally, HC Wainwright lowered their price target on shares of Oculis from $30.00 to $29.00 and set a “buy” rating on the stock in a report on Thursday, March 13th.

Oculis Stock Performance

Shares of OCS traded down $0.23 during midday trading on Wednesday, reaching $18.74. 39,124 shares of the stock were exchanged, compared to its average volume of 45,503. The company has a quick ratio of 4.02, a current ratio of 4.02 and a debt-to-equity ratio of 0.01. The stock’s 50 day simple moving average is $20.96 and its 200 day simple moving average is $17.10. Oculis has a twelve month low of $10.55 and a twelve month high of $23.08. The company has a market cap of $818.23 million, a P/E ratio of -9.71 and a beta of 0.01.

Oculis (NASDAQ:OCS) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.28). Oculis had a negative net margin of 8,043.28% and a negative return on equity of 71.31%. On average, sell-side analysts expect that Oculis will post -2.09 earnings per share for the current year.

Institutional Investors Weigh In On Oculis

Large investors have recently added to or reduced their stakes in the stock. abrdn plc lifted its position in shares of Oculis by 23.0% during the 4th quarter. abrdn plc now owns 1,009,424 shares of the company’s stock valued at $17,150,000 after acquiring an additional 188,871 shares during the period. Citadel Advisors LLC bought a new stake in Oculis during the fourth quarter worth about $389,000. XTX Topco Ltd bought a new stake in Oculis during the fourth quarter worth about $225,000. Bank of America Corp DE increased its holdings in Oculis by 58.2% in the 4th quarter. Bank of America Corp DE now owns 28,980 shares of the company’s stock valued at $493,000 after buying an additional 10,667 shares during the period. Finally, Bellevue Group AG bought a new position in Oculis in the 4th quarter valued at about $170,000. Institutional investors and hedge funds own 22.30% of the company’s stock.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.